Get started

Pharmaceuticals

QLGN - RTTR Merger - Soon to Bounce +30-85% Once it DoesAll, I think we are coming to a double bottom soon. The weekly on QLGN it's obvious there was a massive double top + merger made it sail down. The Question here is where does it end? It is essentially down over 45%. It is going to hit that trend line coming down and most likely fail if you want to swing that. Overall it will recover just a matter of how long. ** DISCLAIMER: If one of there pipeline news comes out thats positive this went down so fast that it will skyrocket on news. So pay attention** Levels I would look at at buy ins Possible bounce now. $5.80 $5.30 Alerts at buy in levels ALSO alerts above current level like 5-10% starting now. that way you get alerted if it does start to take off. Remeber to use volume and make sure it's actually breaking out or has news. Not just some pump on a lower timeframe. Wait for a daily candle. QLGN - RTTR Merger - Soon to Bounce
NASDAQ:QLGN
by DigitalData
BIOTRON - Primed to MOVE!Watching BIOTRON closely. 2 Scenarios: 1. Break of internal trend within the symmetrical triangle will see us return to the .065-.080 region (AREA OF INTEREST). -We've had 2 bounces on the .382 Fib region creating a double top @ .115 Equilibrium -Break of internal uptrend trendline. -Currently broken the center band of bollinger bands. -We've also had a death cross on MACD and is starting to spread. -Waiting on break of support at .088 2. If POSITIVE results are announced shortly for any of BIOTRONS Projects/Programs (Anti Viral Drug Program, HIV Program, HBV Program) We should see a break out of Symmetrical Triangle. -Break of downtrend possible. -Retest of .011 Equilibrium VERY possible. -New Market Structure will form with Higher LOW & Higher HIGH. -Volume will be brought back into the market. -My next target would be major resistance at .014 A very interesting company with real world prospects. I have been following them since the earlier in the year, with Phase 2 HIV-1 Clinical Trials being successful, HBV Pre-Clinical Trials and work on Anti Viral Drug Development with a keen interest on Covid-19. These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!
ASX:BIT
by Trader_Johnni
2
Best Penny Stocks 🚀 to buy and watch in May 2020NASDAQ:EVFM 😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks FDA date of approval - 25th of May Our Strategy with this Stock : This company is a silent player in beer bug vaccination , I'm keeping an eye on it due to the strong upper trend of the company. I'm putting two alarms, one at 2.99 to monitor any anticipatory run up. I'm putting two alarms, one at 2.40 to monitor if it hit the support . What’s the real story : The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply . How can you actually use this ? We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨‍🎓. The Best Part You can follow me and apply my trades for FREE !!! QUESTIONS ? Please comment below , what you have in mind 😊
ELong
by UnknownUnicorn6877177
2
Best Penny Stocks 🚀 to buy and watch in May 2020NASDAQ:AQST 😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks Our Strategy with this Stock : the company will release the drug for Parkinson disease treatment, The analysts are writing the stock at $17 to drive the sheep to buy the stock , while safe Traders will look for a high price of 6.18 $ . I'm putting two alarms, one at 4.79 to monitor any anticipatory run up. I'm putting two alarms, one at 3.37 to monitor if it hit the support . What’s the real story : The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply . How can you actually use this ? We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨‍🎓. The Best Part You can follow me and apply my trades for FREE !!! QUESTIONS ? Please comment below , what you have in mind 😊
NASDAQ:AQSTLong
by UnknownUnicorn6877177
3
Best Penny Stocks 🚀 to buy and watch in May 2020 NASDAQ:AYTU 😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks Our Strategy with this Stock : This company specializes in UV light treatment and the previous history of this company how it strongly reacted with positive news and also negative news . I'm putting two alarms, one at 1.70 to monitor any anticipatory run up. I'm putting two alarms, one at 1.30 to monitor if it hit the support . What’s the real story : The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply . How can you actually use this ? We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨‍🎓. The Best Part You can follow me and apply my trades for FREE !!! QUESTIONS ? Please comment below , what you have in mind 😊
NASDAQ:AYTULong
by UnknownUnicorn6877177
2
OGEN Long into and past earnings! Starting Today!AMEX:OGEN is going to rip into earnings then pull back right before then pop for 100% or more post earnings. Here are my price targets placed for the next week every few days starting with next Monday. DD: OGEN has *1 drug for Oral Mucosis just finished Phase 2 trial, FULL data will be release on earnings call and ironically at the same time they have $15 Million worth of Warrants that will expire the day before. :) Also OGEN as obtained FDA Fast Track approval for this drug and marketing agreements completed in Europe to put it on the shelves immediately if Phase 2 data is good. *1 drug for lowering cholesterol by 70% currently in Phase 1trial, expect results and Ph2 announcement mid/early summer. *$21 Million cash on hand with burn rate of less than 10 Million per year. *This Monday OGEN bought a COVID19 trial drug company with 4,000,000 shares or roughly $1 Million. Trading in a channel, well established bases in this range over the last year or two, no need for extra funding for at least 1 year.
AMEX:OGENLong
by TheStockMarketSniper
1
Best Penny Stocks 🚀 to buy and watch in May 2020 😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks Our Strategy with this Stock : This company is the front Runner for beard vaccinations , anticipatory run up I believe the price could hit $14 Max not as the analysts are putting it between 20 to $30. I put my alarm at 10.9$ .to monitor any anticipatory run up What’s the real story : NASDAQ:INO The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply . How can you actually use this ? We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨‍🎓. The Best Part You can follow me and apply my trades for FREE !!! QUESTIONS ? Please comment below , what you have in mind 😊
NASDAQ:INOLong
by UnknownUnicorn6877177
Best Penny Stocks 🚀 to buy and watch in May 2020 NASDAQ:CLVS 😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks FDA date of approval - 15.05.2020 Our Strategy with this Stock : This company provides prostate cancer therapy . And as you can see there is huge previous spikeability in the company regarding their previous drug in their pipelines . It's going to be the first targeted therapy for prostate cancer Which alone brings a lot of news attention to the analysts already but the average price for the stock to $20 , which is my personal opinion I think it's very far from reality. I'm looking for a price of about 15 to $16 Max !!! I put my alarm at 9.6$ . to monitor any anticipatory run up What’s the real story : The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply . How can you actually use this ? We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨‍🎓. The Best Part You can follow me and apply my trades for FREE !!! QUESTIONS ? Please comment below , what you have in mind 😊
CLong
by UnknownUnicorn6877177
4
VBI vaccines $4 EOY Target Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020 Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS – human clinical study material expected to be available in Q4 2020 Expanded immunologic, tumor, and clinical data from recurrent GBM Phase 2a clinical study of VBI-1901 expected mid-year and Q4 2020 Human proof-of-concept data from Phase 1b/2a study of hepatitis B immunotherapeutic, VBI-2601, expected H2 2020 Net cash proceeds of approximately $54 million added to balance sheet from underwritten public offering in April 2020 11 Million shares bought by insider www.sec.gov
VLong
by jfs2152
2
Ahrvo Daily Movers: Horizon Therapeutics-Bullish on this BiotechAbout Horizon Therapeutics Horizon Therapeutics(ticker: HZNP) is a biopharmaceutical company that focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. HZNP was founded in 2005 and is headquartered in Dublin, Ireland. Ahrvo Stock Rankings Horizon Therapeutics is a top-ten ranked stock on Ahrvo, coming in 6th place (out of over 7,000+ stocks we cover) based on the most recent daily rankings. HZNP has an AhrvoScore (overall score) of 99. Over the last 3 months, Horizon has seen a slight increase in AhrvoScore, up 2 points. Momentum Score, Quality Score, Value Score, and Growth Score are top-notch, clocking in at 94, 80, 99, and 99, respectively. All four sub-scores have increased over the last 3 months. Momentum is up 5 points, Quality up 1 point, Value up 5 points, and Growth up 2 points. Furthermore, Horizon Therapeutics ranks higher than its competitors across all stock scores: Ahrvo Score 99 vs. 35, Momentum Score 94 vs. 62, Value Score 99 vs. 14, Quality Score 80 vs. 18, and Growth Score 99 vs. 42. Ahrvo’s proprietary trading signal also indicates that HZNP is currently a STRONG BUY. Our Take Horizon Therapeutics has performed well relative to the S&P 500 (ticker: SPY) and Nasdaq Biotechnology Index (ticker: IBB). Over the last 6 months, HZNP is up +21%, while the S&P 500 and Biotech Index have returned -8% and +10%, respectively. The company is extremely profitable with net margins of 44%. Last year they earned $573 million on $1.3 billion in revenue. Horizon Therapeutics reports Q1 earnings on Wednesday and is expected to beat analyst expectations. HZNP’s orphan drug portfolio should remain resilient and continue to perform well in the face of economic uncertainty. Orphan drugs are created for extremely rare diseases and drug recipients will need HZNP’s remedies irregardless of what happens with the broader economy. The analyst community is positive on the stock as well. Out of the 12 analysts that cover the company, 10 have HZNP rated as a strong buy (3) or buy (7), with 2 holds. Horizon Therapeutics 12-month median price target is $44.60, representing 25% upside from current levels. -Appo Agbamu, CFA This material is for informational purposes only. Under no circumstances should any information or materials presented be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. Any investment made is at your sole discretion. There are many factors that you must consider when making an investment decision, including, but not limited to, product features, risks, whether or not an investment meets your investment objectives, risk tolerance, and other personalized factors. Investing in securities involves risks, and there is always the potential of losing your entire investment.
HLong
by AhrvoStockApp